Organon

Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.

KENILWORTH, N.J., Nov. 16 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that it has received antitrust clearance from the U.S. Federal Trade Commission (FTC) regarding its planned acquisition of Organon BioSciences N.V. from Akzo Nobel N.V., as announced M...

New fertility drug development techniques by Organon

In the 7th International Symposium on GnRH Analogs in Cancer and Human Reproduction, Organon presented new techniques of development of fertility drugs. Organon scientists have succeeded in customizing the follicle-stimulating hormone(FSH) molecule by adding a hybrid subunit, which extends FSH's ac...

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results

... months ended June 30, 2009 was primarily attributable to lower revenue recognized under Lexicon's alliance agreements with Bristol-Myers Squibb, N.V. organon and Genentech, Inc. For the six months ended June 30, 2009, revenues decreased 61 percent to $7.2 million from $18.5 million for the corresponding pe...

Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder

...des associated with bipolar I disorder in adults as monotherapy. Schering-Plough acquired asenapine in November 2007 through its acquisition of organon BioSciences, which developed the product. Schering-Plough is an innovation-driven, science-centered global health care company. Through its ow...

Schering-Plough Reports Financial Results for 2009 First Quarter

...on Agenda, including the successful acquisition of organon BioSciences," said Hassan. "They triumphed over t...-creating transactions, such as the acquisition of organon BioSciences (OBS). First Quarte... connection with the acquisition of organon BioSciences (a) $118 ...

KineMatik Group Ltd. Appoints Michael G. Jarjour as President & CEO

... Former organon VP of Global Marketing Will Oversee Life Sciences Software Group Cork, Ireland (PRWEB) January 21, 2009 - The KineMatik&tr...

Qforma Appoints Kent Harris as Senior Vice President of Sales

... will be a strong asset to our clients." Harris joined Qforma from organon Pharmaceuticals (now Schering-Plough), where he was responsible for leading...$80 million in annual revenue. In his seven years as a Regional Director at organon Pharmaceuticals, his teams consistently finished in the top 20 percent of t...

Schering-Plough Reports Financial Results for Third Quarter of 2008

... experience, we are seeing that the acquisition of organon BioSciences (OBS) is resulting in a powerful combi... $1.4 billion and $4.2 billion, respectively, from organon BioSciences (OBS) which was acquired on November ... connection with the acquisition of organon BioSciences (a) $136 $- ...

Schering-Plough Announces Transition of Animal Health Leadership

...resident of Intervet International, a position he held since 2002. "Ruurd and Raul played critical leadership roles in our successful combination of organon BioSciences with Schering-Plough over the past year," said Hassan. "I thank Ruurd for his leadership, guidance and important contributions bringing ou...

Schering-Plough to Webcast Presentation by CEO Fred Hassan at Lehman Brothers Eleventh Annual Global Healthcare Conference

...uman prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Ea...

Organon in Medical Technology

FDA Advisory Committee Votes in Favor of SAPHRIS(R) (asenapine) for Acute Bipolar I Disorder and Acute Schizophrenia

...isorder. The application will follow the Centralized Procedure. Schering-Plough acquired asenapine in November 2007 through its acquisition of organon BioSciences, which developed the product. About Schizophrenia Schizophrenia is a chronic, disabling brain disorder that is characteri...

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results

...e three months ended March 31, 2009 was primarily attributable to reduced revenues under Lexicon's alliance agreements with Bristol-Myers Squibb, N.V. organon and Genentech, Inc. Research and Development Expenses: Research and development expenses for the three months ended March 31, 2009 decreased 1...

Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development

...gg allergies. About Nobilon Nobilon International BV, a part of Schering-Plough Corporation, was founded in 2003 and was acquired through the organon BioSciences acquisition in 2007. It has production and R&D facilities in Boxmeer and Oss, the Netherlands. The biotechnology company is dedicated ...

U.S. FDA Issues Complete Response Letter for SAPHRIS(TM) (ASENAPINE) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder

... the potential to be an important option in addressing this need." Schering-Plough acquired asenapine in November 2007 through its acquisition of organon BioSciences, which developed the antipsychotic agent. The New Drug Application (NDA) for asenapine includes data from a clinical trial program involv...

Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention

...enia and acute manic or mixed episodes associated with bipolar I disorder. The company acquired asenapine in November 2007 through its acquisition of organon BioSciences, which developed the product. The Phase III study was a placebo-controlled, double-blind, clinical trial with a randomized with...

Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)

... First product launch following acquisition of organon BioSciences KENILWORTH, N.J., Sept. 10 /PRNewswi...g our first product to market since combining with organon BioSciences," said Fred Hassan, chairman and CEO. ... BRIDION (sugammadex) through its combination with organon BioSciences in November 2007. Important Safety I...

U.S. FDA Issues Action Letter for Sugammadex

...ctions." There were no issues related to the efficacy of sugammadex. Schering-Plough acquired sugammadex in November 2007 through its acquisition of organon BioSciences, which developed the product. Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biop...

BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union

...approval from the Schering-Plough combination with organon BioSciences KENILWO...or approval of a product from our combination with organon BioSciences and is a significant achievement for S... BRIDION (sugammadex) through its combination with organon BioSciences in November 2007. Important Safety I...

New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder

...tive diseases and disease of fibrosis. The company also has multiple development programs with major pharmaceutical companies, including Bayer, Merck, organon and Roche. For further information about KineMed, please visit: http://www.kinemed.com/ About Daiichi Sankyo, Inc. Daiichi Sankyo, Inc., headqua...

European Union's CHMP Issues Positive Opinion on Sugammadex

...uman prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Ea...

Organon in Biological Technology

Schering-Plough Completes Acquisition of Organon BioSciences

Combination Expands Human Health Business, Creates a Global Leader in Animal Health and Strengthens Product Pipeline, Adding Five Phase III Projects KENILWORTH, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced ...

Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.

KENILWORTH, N.J., Oct. 11 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that it has received approval from the European Commission for its planned acquisition of Organon BioSciences, N.V. from Akzo Nobel N.V., as announced March 12. Organon BioSciences is...

SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia

... increase, irritability, dry mouth and nausea. About SAPHRIS Schering-Plough acquired SAPHRIS in November 2007 through its acquisition of organon BioSciences, which developed the psychotropic agent. In the United States, a New Drug Application (NDA) for SAPHRIS sublingual tablets is currently u...

Schering-Plough Reports Financial Results for 2009 Second Quarter

...hich excludes purchase accounting adjustments related to the acquisition of organon BioSciences (OBS) and special, merger- and acquisition-related items. For ...on of intangibles in connection with the acquisition of organon BioSciences (a) $122 $138 $241 $270 Depreciatio...

REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients

...e names, REMERON(R) and Reflex(R), respectively. REMERON is currently available in more than 90 countries worldwide. "REMERON came to us from the organon research laboratories, and we are pleased that this new treatment option will now be available in Japan to help meet the needs of physicians and their...

Sinobiopharma, Inc. Appoints New Director of Marketing

...Group (OTC Bulletin Board: SNBP) is pleased to announce the appointment of Ms. Yan Tan as Director of Marketing. Ms. Tan joins Sinobiopharma from organon Pharmaceutical Co., Ltd., Netherlands. She served as a China-based Unit Marketing Director for Organon, which was recently sold to Schering-Plough. Pr...

Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries

...f human life. About Nobilon Nobilon International BV, a part of Schering-Plough Corporation, was founded in 2003 and was acquired through the organon BioSciences acquisition in 2007. It has production and R&D facilities in Boxmeer and Oss, the Netherlands. The biotechnology company is dedicated ...

Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder

...ice president and president, Schering-Plough Research Institute. Schering-Plough acquired asenapine in November 2007 through its acquisition of organon BioSciences, which developed the antipsychotic agent. The New Drug Application (NDA) for asenapine includes data from a clinical trial program involv...

Qforma Appoints Two New Executives

... Wiggs has served in various sales and sales management positions and brings to Qforma over 10 years of pharmaceutical industry experience. He joined organon Pharmaceuticals USA (now Schering-Plough) as a sales representative in 1999 and was promoted to district manager in 2002. In the latter role, Wiggs w...

Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial

...port a regulatory submission for the approval of asenapine in Europe. Schering-Plough acquired asenapine in November 2007 through its acquisition of organon BioSciences, which developed the product. Asenapine is currently under review by the U.S. Food and Drug Administration for the treatment of schizophre...